rs1067352 - CAMKMT

Magnitude 2.2 · 1 study on file

Reported associations

• Genome-wide association analysis to predict optimal antipsychotic dosage in schizophrenia: a pilot study. - Journal of neural transmission (Vienna, Austria : 1996) (2016) · Koga AT, Strauss J, Zai C, Remington G, De Luca V · PubMed 26821981

  In recent years, several studies have investigated genetic polymorphisms of antipsychotic drug-metabolizing enzymes and receptors. However, most studies focused on drug response and very few have investigated the genetic influence on antipsychotic dosage. The aim of the present study is to test the association between antipsychotic dosages at genome-wide level. The current dosage of antipsychotic medications was collected from 79 schizophrenia patients. The dosage was standardized using three different methods: chlorpromazine equivalent (CPZe), defined daily dose (DDD), and percentage of maximum dose (PM %). The patients were then genotyped using the Illumina HumanOmni2.5-8 BeadChip Kit. All markers were screened for significance using linear regression, and the p values were visualized u

Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.